Full Answer
Who buys zomedica (Zom) stock?
7 hours ago · Zoom closed the trading session up by 11.6%. So what. On Thursday, Zoom said it struck a deal to acquire Solvvy, which owns an artificial intelligence-powered automation platform for customer support.
Where can I buy shares of Zom?
Zomedica Announces First Quarter 2022 Revenues of $3.8 Million; 74% Gross Margin & $192.3 Million in Cash; Revenue up 38% from 2021 Combined Revenues. All …
Will zomedica stock outperform or underperform the S&P 500 over the long term?
Apr 24, 2022 · Zomedica's stock was trading at $0.2078 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZOM shares have increased by 15.5% and is now trading at $0.24. View which stocks have been most impacted by COVID-19.
Is Zom a buy or sell in 2020?
Feb 04, 2021 · As part of this, Zomedica plans to launch sales on March 30, meaning that a huge catalyst for ZOM stock is just a few weeks away. Through the deal with Miller, Truforma will end up in the hands of ...
Why is Zomedica stock going up?
Will ZOM stocks go back up?
Is ZOM stock a good buy?
Is Zomedica a good long-term investment?
Will Bionano Genomics stock go up?
The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 8.00, with a high estimate of 12.00 and a low estimate of 6.00. The median estimate represents a +469.40% increase from the last price of 1.41.
Is Castor Maritime a buy?
finds support from accumulated volume at $1.79 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Why is ZOM dropping?
Is Zomedica undervalued?
How high does IDEX go?
The 2 analysts offering 12-month price forecasts for Ideanomics Inc have a median target of 2.00, with a high estimate of 3.00 and a low estimate of 1.00. The median estimate represents a +260.30% increase from the last price of 0.56.
Could Zomedica be a millionaire maker?
How has Zomedica's stock been impacted by COVID-19 (Coronavirus)?
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organ...
When is Zomedica's next earnings date?
Zomedica is scheduled to release its next quarterly earnings announcement on Tuesday, May 10th 2022. View our earnings forecast for Zomedica .
How were Zomedica's earnings last quarter?
Zomedica Corp. (NYSEAMERICAN:ZOM) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per shar...
What guidance has Zomedica issued on next quarter's earnings?
Zomedica issued an update on its FY 2021 earnings guidance on Monday, March, 14th. The company provided earnings per share (EPS) guidance of for th...
Who are Zomedica's key executives?
Zomedica's management team includes the following people: Mr. Robert Cohen , CEO & Director (Age 63, Pay $412.79k) Ms. Ann Marie Cotter CPA , C...
Who are some of Zomedica's key competitors?
Some companies that are related to Zomedica include Protagonist Therapeutics (PTGX) , Keros Therapeutics (KROS) , Myovant Sciences (MYOV) , Axs...
What is Zomedica's stock symbol?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
Who are Zomedica's major shareholders?
Zomedica's stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (2.93%), BlackR...
Which institutional investors are selling Zomedica stock?
ZOM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Commonwealt...
How much is Zomedica stock worth in 2021?
The Zomedica Pharmaceuticals Corp stock price gained 3.73% on the last trading day (Friday, 9th Jul 2021), rising from $0.71 to $0.74. During the day the stock fluctuated 4.11% from a day low at $0.72 to a day high of $0.75. The price has fallen in 6 of the last 10 days and is down by -12.33% for this period. Volume fell on the last day by -6 million shares and in total, 18 million shares were bought and sold for approximately $13.09 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Is Zomedica Pharmaceuticals Corp a negative stock?
Zomedica Pharmaceuticals Corp holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.
How do hedge funds control the price?
very common strategy to be used by hedge funds to control the price. simply buy and hold, this price is a discount. good luck.
Is Zomedica a good stock?
Zomedica being added to MSCI proves it's seen as a growth stock, potentially even having dividends in the future. This addition can potentially increase trading and volume. The MSCI indexes are similar to the Dow Jones Averages or the S&P 500. This is very good news.
Is a zom part of an index?
Remember ZOM is part of an index. Institutions buy the underlying symbols in the index. Hence a vast majority of institutions hold ZOM.
Where does Zomedica trade?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
What is Zomedica Corp?
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
What is the P/E ratio of Zomedica?
The P/E ratio of Zomedica is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is there enough data for Zomedica?
There is not enough analysis data for Zomedica.
Does Zomedica pay dividends?
Zomedica does not currently pay a dividend.
A Closer Look at ZOM Stock
A year ago, the situation of Zomedica’s investors was much better than it is today. Amazingly, ZOM stock shot up from 10 cents in late 2020 to a 52-week high of $2.91 on Feb. 8, 2021.
First, the Bad News
Now I’m not going to sugarcoat the value proposition of Zomedica. It’s a small company with lackluster financials, to put it politely.
A Shocking Discovery
What was this acquisition? That is the billion-dollar question for Zomedica’s stakeholders.
The Bottom Line
Make no mistake about it: the acquisition of PulseVet is a major gamble for Zomedica. Only time will tell whether sound-wave technology will be widely accepted by veterinarians and pet owners.
Who is Zomedica Corp?
ANN ARBOR, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that it had acquired the Pulse Veterinary Technologies businesses for $70.9 million in an all-cash, stock transaction. Pulse Veterinary Technologies (“PulseVet”) is a world leader in electro-hydraulic shock wave technology for the treatment of a wide vari
Is Zomedica publicly traded?
Founded in 2013 and publicly-traded since 2016, Zomedica (ZOM) is a relatively new organization. However, this veterinary-focused medical device company has seen tremendous interest among growth investors of late. Why? Well, there are a number of reasons for this. Among the core reasons for the surging interest in pet-friendly tech plays is the growth we've seen in pet adoption rates throughout the pandemic. As owners are discovering, a pet adoption is a multi-year (or even multi-decade) long co
Is Zomedica in the development stage?
Zomedica, which is in the development stage, recorded no revenues in 2020. The 2020 net loss resulted from research and development (“R&D”) expenses of approximately $8.0 million, general and administrative (“G&A”) expenses of approximately $6.0 million, and professional fees of approximately $2.2 million.
Is Zomedica a meme?
As has been the case for several months, Zomedica (NYSEAMERICAN:ZOM) continues to tread water. ZOM stock, a pet diagnostics play and reputed meme stock, has struggled to bounce back after big declines last spring. Source: Postmodern Studio / Shutterstock.com Said decline came right after shares, trading for well under $1 at the start of 2021, zoomed to as much as $2.91. The move may or may not have been the product of Reddit traders stampeding into it with full force. But I wouldn’t put too much
What is the big breakout in Zom?
This company is on the cusp of commercializing a breakthrough technology platform that could meaningfully disrupt the $2.8 billion and rapidly growing vet diagnostics market.
What is the big picture bull thesis on ZOM?
That context, of course, is that pets are becoming humans, and as such, we are spending more and more money on all-things pet-care-related.
A Closer Look at ZOM Stock
While it’s difficult to prove this assertion, it certainly appears that ZOM stock received a huge boost from Reddit’s users.
Literally Giving It Away
This update was released after Heaton had been in the CEO position for “just over 60 days,” so we shouldn’t expect the company to have changed much at that point.
The Bottom Line
The company’s strategy will either turn out to be brilliant or disastrous. Are you really prepared to wager your hard-earned capital on the success of Zomedica’s “Customer Appreciation Program?”